An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
NCT01368276
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
Talimogene Laherparepvec
DRUG:
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Sponsor
BioVex Limited